| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/26/2011 | CN101199731B Active external hair combination liquid and preparing method thereof |
| 01/26/2011 | CN101189217B Process for producing an aminomethyl thiazole compound |
| 01/26/2011 | CN101185640B Lomoxicam sustained release tablet and preparation method thereof |
| 01/26/2011 | CN101181235B Tantudinun sustained-release implantation agent for curing entity tumour |
| 01/26/2011 | CN101181231B Sustained-release implantation agent of urotrotiken |
| 01/26/2011 | CN101141965B Pharmaceutical composition for regenerating myofibers in the treatment of muscle injuries |
| 01/26/2011 | CN101139330B Compound having protecting cell oxidation damaged reactivity, preparation method and uses thereof |
| 01/26/2011 | CN101107014B Stabilisation of glucocorticoid esters with acids |
| 01/26/2011 | CN101084190B 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists |
| 01/26/2011 | CN101083987B S-tryazolyl alpha,-mercaptoacetanliides as inhibitors of HIV reverse transcriptase |
| 01/26/2011 | CN101081229B Plasma subtitute injection using hydroxyethyl group amylum as blood plasma dilatancy agent |
| 01/26/2011 | CN101077875B Boronic ester and acid compounds, synthesis and uses |
| 01/26/2011 | CN101066259B Solid dispersion of higher fatty alcohol and its prepn |
| 01/26/2011 | CN101058561B Diphenylurea derivative for inhibiting protein kinase, and composition and use thereof |
| 01/26/2011 | CN101053369B Feed additive for fowls and domestic animals and preparation method thereof |
| 01/26/2011 | CN101045063B Clarithromycin water soluble preparation for injection use |
| 01/26/2011 | CN101040863B Medicine monocase compound for treating alzheimers disease |
| 01/26/2011 | CN101007798B Benzodioxole derivatives and their preparation method and medicinal uses |
| 01/26/2011 | CN101002827B Micro-emulsion of mint oil with slow-releasing property, and its preparing method |
| 01/25/2011 | USRE42072 High transport rates of hormones delivered across cell membranes, facilitating more efficient delivery of drugs and diagnostic agents by using a viscous fluid comprising a polysaccharide a form of hydrogel, lipogel or sols; drug delivery to mucous membranes; gastrointesinal systems |
| 01/25/2011 | US7875745 Compounds having lysophosphatidic acid receptor antagonism and uses thereof |
| 01/25/2011 | US7875744 modulators of peroxisome proliferator activated receptors; treating diabetes, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cardiovascular diseases; dyslipidema; [4-[[2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]-acetic acid |
| 01/25/2011 | US7875733 Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation |
| 01/25/2011 | US7875728 Hydrazonopyrazole derivatives and their use as therapeutics |
| 01/25/2011 | US7875727 Benzimidazole vascular damaging agents |
| 01/25/2011 | US7875726 Thiazolidin-4-one derivatives |
| 01/25/2011 | US7875721 Modulators of estrogen receptor alpha/beta G protein-coupled receptor 30, e.g., 1-(4-(6-Bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)1-ethanone; treating diseases such as cancer, neurodegenerative disorders, obesity, osteoporosis, and symptoms of menopause |
| 01/25/2011 | US7875712 inhibitors of apoptosis and IL-1 beta secretion; mediate cell apoptosis and inflammation; good cell penetration and pharmacokinetic properties; [3S/R(2S)]3-[2-(Carbazol-9-yl-2-oxo-ethyl)-pentanoylamino]-5-fluoro-4-oxo-pentanoic acid |
| 01/25/2011 | US7875677 Micellar drug delivery systems for hydrophobic drugs |
| 01/25/2011 | US7875652 Method and composition for treating pain or tinnitus aureum |
| 01/25/2011 | US7875651 Epicatechin for hypertension treatment |
| 01/25/2011 | US7875650 Compounds and methods to increase anti-P-glycoprotein activity of baicalein by alkylation on the A ring |
| 01/25/2011 | US7875649 7-(1,4-dioxenyl) doxycycline; Therapy against tetracycline-resistant organisms; bactericides; bacteriostats; escherichia; straphococcus; enterococcus; anticancer agents; antidiabetic agents |
| 01/25/2011 | US7875648 for congenital muscular dystrophy or myopathy resulting from mutations in any of the collagen VI genes selected from the group consisting of Col6A1, Col6A2, and Col6A3; administered orally; normalizes the pathological changes at the ultrastructural level in mitochondria of muscle tissue |
| 01/25/2011 | US7875647 Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists |
| 01/25/2011 | US7875646 Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl] sulfonamide, their preparation and their application in therapeutics |
| 01/25/2011 | US7875645 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders |
| 01/25/2011 | US7875644 1-acyldihydropyrazole derivatives |
| 01/25/2011 | US7875643 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors |
| 01/25/2011 | US7875642 3-[1-(4-Chlorophenyl)-trans-3-fluorocyclobutyl]-4,5-dicyclopropyl-r-4H-1,2,4-triazole anhydrate; Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment |
| 01/25/2011 | US7875641 new forms of 2-butyl-1-[2'-(1H-tetrazol-5-yl)bifenyl-4-yl-methyl]spiro[2-imidazoline-4.1'-cyclopentane]-5-one; antagonist of angiotensin-II receptors |
| 01/25/2011 | US7875640 Compounds as cannabinoid receptor ligands |
| 01/25/2011 | US7875639 Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection |
| 01/25/2011 | US7875638 desoxyepothilone A and B; Fludelone; anticarcinogenic agents; drug resistance; water solubility for formulability; industrial scale; cytotoxic or growth inhibitory effects on CAG myeloma cells lines; ability to polymerize tubulin; minimum toxicity; isomerization of the double bonds in the ring |
| 01/25/2011 | US7875637 Benzimidazole derivative and use as a II receptor antagonist |
| 01/25/2011 | US7875636 Pyridyl amide T-type calcium channel antagonists |
| 01/25/2011 | US7875633 Phenylpyridone derivative |
| 01/25/2011 | US7875632 combination of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide andmonoamine oxidase inhibitor (MAO-I ) selected from tranylcypromine (Parnate), phenelzine (Nardil), maprotiline, and isocarboxazid (Marplan); anti-psychotic agent; dosage form; capsule |
| 01/25/2011 | US7875631 e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed |
| 01/25/2011 | US7875630 reacting exo-8-methyl-8-azabicyclo[3.2.1]octan-3-thiol with mutilin 14-methanesulfonyloxyacetate in the presence of a tetra-n-butylammonium hydrogensulfate phase transfer catalyst, 4-methyl-2-pentanone, and aqueous NaOH to form mutilin 14-(exo-8-methyl-8-azabicyclo[3.2. 1]oct-3-ylsulfanyl)-acetate |
| 01/25/2011 | US7875629 Quinolinone compounds as 5-HT4 receptor agonists |
| 01/25/2011 | US7875628 Cyclopamine analogues and methods of use thereof |
| 01/25/2011 | US7875627 Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof |
| 01/25/2011 | US7875626 Therapeutic agents |
| 01/25/2011 | US7875625 3-guanidinocarbonyl-2-methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ylmethyl hydrogen sulfate, inhibitory effect on an Na+/H+ exchanger; |
| 01/25/2011 | US7875624 Modulating and measuring cellular adhesion |
| 01/25/2011 | US7875623 composition is treated with a thiol-containing compound under conditions sufficient to remove Michael acceptors such as 14-hydroxycodeinone |
| 01/25/2011 | US7875622 Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
| 01/25/2011 | US7875621 Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors |
| 01/25/2011 | US7875620 Methods of treating microbial infections |
| 01/25/2011 | US7875619 Hetero substituted sodium channel blockers |
| 01/25/2011 | US7875618 Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders |
| 01/25/2011 | US7875617 N-[4-(2-methoxyphenyl)piperazin-1-yl)butyl]-3,4-dihydro-6-fluoro-2-naphthamide for treating neuropsychological disorder selected from Parkinson's disease, schizophrenia and depression; partial agonists or antagonists of the dopamine D3 receptor |
| 01/25/2011 | US7875616 Use of tyrosine kinase inhibitor to treat diabetes |
| 01/25/2011 | US7875615 Substituted triazole derivatives as oxytocin antagonists |
| 01/25/2011 | US7875614 Phthalazinones |
| 01/25/2011 | US7875613 Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |
| 01/25/2011 | US7875612 Folate mimetics and folate-receptor binding conjugates thereof |
| 01/25/2011 | US7875611 Ion channel modulating compounds and uses thereof |
| 01/25/2011 | US7875610 Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
| 01/25/2011 | US7875609 3-(4-chlorophenyl)-1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)urea; treatment of the cancer of the parathyroid and the digestive tract; osteoporosis, osteopaenia and Paget's disease, rheumatoid arthritis and osteoarthritis |
| 01/25/2011 | US7875608 Substituted 8-[6-amino-3pyridyl]xanthines |
| 01/25/2011 | US7875607 7,8-bicycloakyl-chroman derivatives |
| 01/25/2011 | US7875606 Izoxazoline derivative and herbicide |
| 01/25/2011 | US7875605 1-Benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole; 1-[[5-Bromo-1-(2-Bromo-4-methoxybenzenesulfonyl)-indo1-3-yl]methyl][1,4]diazepane; useful for treating psychotic and neurodegenerative disorders e.g. schizophrenia, Alzheimer's disease, Parkinson's disease and Huntington's chorea |
| 01/25/2011 | US7875604 Compounds that inhibit HIV particle formation |
| 01/25/2011 | US7875603 phenyl-, pyridyl-, pyrimidyl- and purine- derivatives; anticarcinogenic agent; solid tumor: breast, colorectal, lung, prostate, and ovarian |
| 01/25/2011 | US7875602 Camptothecin derivatives as chemoradiosensitizing agents |
| 01/25/2011 | US7875601 Cancer treatment with epothilones |
| 01/25/2011 | US7875600 To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide |
| 01/25/2011 | US7875599 3 beta -hydroxy-17-(1H-imidazole-1-yl)androsta-5,16-diene for treatment of prostate cancer; inhibitor of 17-alpha-hydroxylase/17,20 lyase/17,20 desmolase ( a cytochrome p-450 enzyme ) |
| 01/25/2011 | US7875598 yeast or fungal acitvity inhibiting using a composition comprising polyphyllin D ; for oral microbial infections, including periodontal disease and dental caries; (3 beta ,25R)-spirost-5-en-3-yl O- alpha -L-arabinofuranosyl-(1 --> 4)-O-[6-deoxy- alpha -L-mannopyranosyl-(1 --> 2)]- beta -D-glucopyranoside |
| 01/25/2011 | US7875597 Intravenously administering a bisphosphonate |
| 01/25/2011 | US7875596 Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
| 01/25/2011 | US7875595 5-[6-Amino-2-(2-hydroxy-adamantan-2-ylethynyl)-purin-9-yl]-3,4-dihydroxy-tetrahydro-furan-2-carboxylic acid cyclopropylamide for the treatment of inflammatory activity in mammalian tissue; A2A adenosine receptor agonist; autoimmune stimulation, allergic diseases, skin diseases, infectious diseases |
| 01/25/2011 | US7875594 Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents |
| 01/25/2011 | US7875592 Sulfated oligosaccharide derivatives |
| 01/25/2011 | US7875591 comprising a scaffold coated with a protein having at least 83% identity to the amino acid sequence of the core protein of domain I of a mammalian perlecan, wherein at least one glycosaminoglycan is attached to the protein; induce replication and/or differentiation of connective tissue cells |
| 01/25/2011 | US7875590 using an injectable or implantable rod-shaped formulation for delivery of osteogenic proteins to treat osteoporotic and/or osteopenic bone; bone morphogenic proteins |
| 01/25/2011 | US7875588 Methods of therapy using pharmaceutical composition for thrombin peptide derivatives |
| 01/25/2011 | US7875450 Virus-like particles for the induction of autoantibodies |
| 01/25/2011 | US7875342 Porous ceramic composite bone grafts |
| 01/25/2011 | US7875310 Residual solvent extraction method and microparticles produced thereby |
| 01/25/2011 | US7875299 Compositions and methods for enhancing or treating female sexual response |
| 01/25/2011 | US7875292 Orally disintegrable tablets |
| 01/25/2011 | US7875290 Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form |
| 01/25/2011 | US7875282 A biocompatible, implantable structure such as a stenthaving a basecoat matrix of hexfluoropropylene-vinylidene fluoride copolymer including dosages of rapamycin and 2-methoxyestradiol; polybutyl methacrylate over coat tocontrol elution; antirestenotic and antiproliferativeagents; synergistic |
| 01/25/2011 | US7875279 intermediates of the mevalonate-independent pathway for isoprenoid biosynthesis are enriched by deleting or inactivating genes; asthma, morbus Crohn, colitis ulcerosa, multiple sclerosis and chronic bronchitis and immune and auto-immune diseases and allergies and bone diseases and osteoporosis |
| 01/25/2011 | US7875271 Ophthalmic composition comprising xanthan gum and glucose |
| 01/25/2011 | US7875270 Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells |